Journal of Substance Abuse Treatment
Volume 29, Issue 4 , Pages 307-312 , December 2005

Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms

  • Marek C. Chawarski, Ph.D.

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Yale University School of Medicine, CMHC/SAC, Suite S206, 34 Park St., New Haven, CT 06519.
    • ,
  • David E. Moody, Ph.D.

      Affiliations

    • Center for Human Toxicology, University of Utah, Salt Lake City, UT, USA
    • ,
  • Juliana Pakes, M.S.

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • ,
  • Patrick G. O'Connor, M.D.

      Affiliations

    • Department of Medicine, Yale University School of Medicine, New Haven, CT, USA
    • ,
  • Richard S. Schottenfeld, M.D.

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

Received 7 March 2005 ,Revised 6 May 2005 ,Accepted 23 August 2005.

References 

  1. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. Journal of Pharmacology & Experimental Therapeutics. 1988;247:47–53
  2. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine. 2003;349:949–958
  3. Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: Lack of dose proportionality. Clinical Pharmacokinetics. 2004;43:329–340
  4. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine. 2000;343:1290–1297
  5. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750–2755
  6. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous & Mental Disease. 1993;181:358–364
  7. Kuhlman JJ, Lalani S, Magluilo J, Levine B, Darwin WD, Johnson RE, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. Journal of Analytical Toxicology. 1996;20:369–378
  8. Kuhlman JJ, Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction. 1998;93:549–559
  9. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Kintaudi P, et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction. 1998;93:475–486
  10. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. 2002;CD002207
  11. McGettigan P, Henry DA, Hennesy S. Basic principles of clinical pharmacology relevant to pharmacoepidemiology studies. In:  Storm BL editors. Pharmacoepidemiology. New York: Wiley & Sons; 2000;
  12. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science. 1980;207:657–659
  13. Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT. Bioavailability of sublingual buprenorphine. Journal of Clinical Pharmacology. 1997;37:31–37
  14. Mendelson J, Upton RA, Jones RT. Buprenorphine pharmacokinetics: Bioavailability of an 8 mg sublingual tablet formulation. In:  Harris LS editors. Problems of Drug Dependence 1995: Proceedings of the 57th Annual Scientific Meeting, NIDA Research Monograph Series #162. Washington, DC: US Government Printing Office; 1996;p. 112
  15. Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic–electrospray ionization–tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Analytical Biochemistry. 2002;306:31–39
  16. Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, et al. Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tables and liquid formulations. Journal of Clinical Pharmacology. 1999;39:619–623
  17. O'Connor PG, Chawarski MC, Pakes J, Schottenfeld RS. A pilot study of three dose schedules for thrice-weekly administration of buprenorphine. In: Problems of Drug Dependence 1997: Proceedings of the 59th Annual Scientific Meeting. 1998;(NIDA Research Monograph 178)
  18. Schottenfeld RS, Pakes J, O'Connor P, Chawarski MC, Oliveto A, Kosten TR. Thrice-weekly versus daily buprenorphine maintenance. Biological Psychiatry. 2000;47:1072–1079
  19. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry. 1997;54:713–720
  20. Schuh KJ, Johanson CE. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug and Alcohol Dependence. 1999;56:55–60
  21. Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug and Alcohol Dependence. 2004;74:37–43
  22. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry. 1994;151:1025–1030

PII: S0740-5472(05)00173-X

doi: 10.1016/j.jsat.2005.08.011

Journal of Substance Abuse Treatment
Volume 29, Issue 4 , Pages 307-312 , December 2005

Article Tools

* Image Usage & Resolution